<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017354</url>
  </required_header>
  <id_info>
    <org_study_id>KEK39/09</org_study_id>
    <secondary_id>2009DR2248</secondary_id>
    <nct_id>NCT01017354</nct_id>
  </id_info>
  <brief_title>Zurich Disability Prevention Trial</brief_title>
  <acronym>ZDPT</acronym>
  <official_title>Monthly Vitamin D to Improve Vitamin D Status and Maintain Function in Pre-frail Older Individuals Living at Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project was designed to optimizing vitamin D status in prefrail seniors age 70+ living&#xD;
      at home and prevent their functional decline. We test 3 arms of monthly vitamin D&#xD;
      supplementation. Intermittent dosing will improve adherence and simplify vitamin D&#xD;
      supplementation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a double-blind, randomized controlled trial to test the effectiveness of a&#xD;
&#xD;
        1. Active I (n=70): monthly high-dose vitamin D3 supplement dose (60'000 IU/month,&#xD;
           equivalent to 2000 IU daily),&#xD;
&#xD;
        2. Active II (n=70): or a monthly standard vitamin D3 supplement dose combined with 25(OH)D&#xD;
           (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg&#xD;
           per day)&#xD;
&#xD;
        3. Control (n=70): compared to a standard vitamin D3 supplement dose (24'000 IU/month,&#xD;
           equivalent to 800 IU daily)&#xD;
&#xD;
      All individuals will be advised to consume calcium from natural food sources in a daily dose&#xD;
      of 600-800 mgs a day, including milk products. Maximal intake of supplemental calcium is&#xD;
      restricted to 250 mg per day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional decline (proportion of individuals with functional decline based on binary repeated measure assessment across 4 lower extremity tests)</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improving 25-hydroxyvitamin D levels in late winter and late summer - Percent of individuals reaching desirable 25-hydroxyvitamin D levels of at least 75 nmol/l in late winter and in late summer</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety at baseline, 2 weeks, 6 months, 12 months • Serum calcium adjusted for albumin • Serum creatinine • Urinary calcium/creatinine ratio</measure>
    <time_frame>2 weeks, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance/Gait while walking combined with a cognitive task</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Test Battery</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 4 m walk</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Musculoskeletal pain assessed with the McGill pain map</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic and diastolic blood pressure, heart rate</measure>
    <time_frame>6 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of falls, all, injurious falls (diary, monthly phone calls, and hotline)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grip strength</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density at the spine and hip, whole body</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incident vertebral fractures (iDXA morphometry)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle mass, incident sarcopenia</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization: in collaboration with insurance companies for outpatient and inpatient health care costs.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF 12 / EuroQuol)</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital admission (fall-related injury, infections, other)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum N-telopeptides and other markers of bone remodeling</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper and lower respiratory tract infections, any infections, infections that lead to inpatient care</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Community-dwelling Seniors</condition>
  <condition>History of a Fall in the Previous 12 Months</condition>
  <arm_group>
    <arm_group_label>High-dose vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard vitamin D + 25(OH)D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hidroferol® (ES)</intervention_name>
    <description>24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month</description>
    <arm_group_label>standard vitamin D + 25(OH)D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ViDe3 (CH)</intervention_name>
    <description>60000 vitamin D3 orally and once per month</description>
    <arm_group_label>High-dose vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ViDe3 (CH)</intervention_name>
    <description>24000 Vitamin D3 orally and once per month</description>
    <arm_group_label>standard vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 70+&#xD;
&#xD;
          -  Fall in the last 12 months before screening (with or without a fracture)&#xD;
&#xD;
          -  Living at home (community-dwelling)&#xD;
&#xD;
          -  Men or women&#xD;
&#xD;
          -  Mobile with or without walking aid - have to be able to use public transportation to&#xD;
             attend the clinical visits at the trial centre&#xD;
&#xD;
          -  Score of at least 27 at the screening Folstein Mini Mental test + normal clock test&#xD;
&#xD;
          -  Patient understands the study procedures, alternative treatments available and risks&#xD;
             involved with the study, and voluntarily agrees to participate by giving a written&#xD;
             informed consents.&#xD;
&#xD;
          -  Patient meets the entry minimal requirements based on routine clinical laboratory&#xD;
             safety screening tests and the Folstein mini mental status (score 27+ required)&#xD;
             performed at the Screening Visit.&#xD;
&#xD;
          -  Patient is willing to perform all study tests, attend all required office visits, and&#xD;
             provide blood and urine samples.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Serum calcium adjusted for albumin of &gt; 2.6 nmol/l&#xD;
&#xD;
          -  Pathologic fracture in the last year (except for fractures due to osteoporosis)&#xD;
&#xD;
          -  Chemo therapy / Radiation due to cancer in the last year&#xD;
&#xD;
          -  Treatment which has an effect on bone metabolism (e.g. bisphosphonate, PTH,&#xD;
             calcitonin, chronic cortisone intake &gt; XYmg/day for more than XY month/years (except&#xD;
             for inhalation and sporadic infiltration))&#xD;
&#xD;
          -  Oral vitamin D intake of more than 800 IU per day&#xD;
&#xD;
          -  Unwilling to stop calcium supplementation and vitamin D supplementation during the&#xD;
             trial (maximal calcium supplement intake 250mg/d; no additional vitamin D&#xD;
             supplementation)&#xD;
&#xD;
          -  Severe visual or hearing impairment&#xD;
&#xD;
          -  Unwilling or unable to take study medication&#xD;
&#xD;
          -  Diseases with a risk of recurrent falling (e.g. Parkinson's disease/syndrome,&#xD;
             Hemiplegia after stroke, symptomatic stenosis of the spinal canal, polyneuropathy,&#xD;
             epilepsy, recurring vertigo, recurring syncope)&#xD;
&#xD;
          -  BMI &gt;= 40&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 15 ml/min (estimated Creatinine Clearance Cockcroft&#xD;
             and Gault)&#xD;
&#xD;
          -  Malabsorption syndrome (celiac diseases, inflammatory bowl disease)&#xD;
&#xD;
          -  Diseases that may enhance serum calcium: sarcoidosis, lymphoma, primary&#xD;
             hyperparathyroidism&#xD;
&#xD;
          -  kidney stone in the last 10 years&#xD;
&#xD;
          -  Abnormal indices of calcium metabolism, uncontrolled hypocalcemia.&#xD;
&#xD;
          -  Patient heavily consumes alcohol containing products defined as greater than (&gt;) 3&#xD;
             drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.&#xD;
&#xD;
          -  Patient is unlikely to adhere to the study procedures, to keep appointments, or is&#xD;
             planning to relocate during the study.&#xD;
&#xD;
          -  Patients who are planning a stay in a &quot;sunny&quot; location (e.g. winter sun resort) for&#xD;
             more than two months per year&#xD;
&#xD;
          -  Medication which has an effect on 25-hydroxyvitamin D level (e.g. certain&#xD;
             anticonvulsants (e.g. Phenobarbital, Carbamazepin, Phenytoin))&#xD;
&#xD;
          -  M. Paget (Ostitis deformans)&#xD;
&#xD;
          -  inflammatory arthritis (e.g. rheumatoid arthritis, reiter syndrome, psoriasis&#xD;
             arthritis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Bischoff Ferrari, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Centre on Aging and Mobility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Centre on Aging and Mobility</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>function</keyword>
  <keyword>falls</keyword>
  <keyword>25-hydroxyvitamin D</keyword>
  <keyword>disability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

